Physical Activity in Rectal Cancer Survivors
Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · May 29, 2024
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
The goal of this clinical trial is to administer and determine the feasibility of a personalized physical activity intervention for rectal cancer survivors. Structured physical activity interventions will be administered over a three-month period. An exit interview will be conducted at the completion of this time period.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosis of Stage I-III cancers of the rectum/rectosigmoid.
- • 2. Age 18 or older
- • 3. Three months to 5 years post-treatment completion
- • 4. Have a rectal or anal anastomosis with a LARS score of 21-42
- • 5. At least 10 participants must be racial/ethnic minority (Black/African American, Hispanic/Latino)
- • 6. Ability to be physically active and cleared by MD
- • 7. Patients must be able to read and understand English.
- • 8. Participants must sign the informed consent form
- • The study is open to anyone regardless of gender or ethnicity. Efforts will be made to extend the accrual to a representative population, but in a trial which will accrue 20 subjects, a balance must be struck between subject safety considerations and limitations on the number of individuals exposed to potentially toxic or ineffective treatments on the one hand and the need to explore gender, racial, and ethnic aspects of clinical research on the other. If differences in outcome that correlate to gender, racial, or ethnic identity are noted, accrual may be expanded, or additional studies may be performed to investigate those differences more fully.
- Exclusion Criteria:
- • 1. Patients failing to meet all the above inclusion criteria will be excluded from the study.
About Abramson Cancer Center At Penn Medicine
The Abramson Cancer Center at Penn Medicine is a leading academic institution dedicated to advancing cancer research, treatment, and prevention. As part of the University of Pennsylvania, the center integrates cutting-edge scientific discovery with comprehensive clinical care, offering patients access to innovative therapies and clinical trials. Renowned for its multidisciplinary approach, the Abramson Cancer Center collaborates with experts across various specialties to deliver personalized treatment plans while fostering a supportive environment for patients and their families. Committed to improving outcomes and quality of life for cancer patients, the center is at the forefront of groundbreaking research initiatives and educational programs aimed at transforming cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Erica Pettke, MD, MPH, FACS
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported